Drugs / Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01145508 | Aug 2010 → Oct 2012 | hormone-resistant prostate carcinoma, prostate adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01145508 ↗ |
| Route | Subcutaneous | “Given SC” NCT01145508 ↗ |